Global Orphan Drugs Market Analysis and Forecast 2016-2026: ~$400 Billion Market Breakdown by Drug Type, Therapy Class, Drug, Disease Type, Indication, Phase, Distribution Channel & Geography – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Orphan Drugs Market Analysis 2019” report has been added to ResearchAndMarkets.com’s offering.

The Global Orphan Drugs market is expected to reach $398.93 billion by 2026 growing at a CAGR of 13% during the forecast period.

The demand for orphan drugs has increased significantly owing to the surge in prevalence of rare diseases. However, the limited patient pool for clinical trials and product marketing is hampering the market. Moreover, growth in novel indications for known orphan drugs and untapped emerging economies are expected to provide new market opportunities to orphan drug manufacturers in the near future.

Based on the Therapy Class, the Oncology segment is estimated to have a lucrative growth due to the rise in the number of patients suffering from different types of cancers. This also increases the demand for novel therapeutics, which as per the report will bode well for the global orphan drugs market.

The key vendors mentioned are Alexion Pharmaceuticals Inc, Amgen Inc, AstraZeneca Plc, Bayer AG, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Company Limited, GlaxoSmithKline Plc, Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Novo Nordisk A/S, and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in this Report

• How this market evolved since the year 2016
• Market size estimations, forecasts and CAGR for all the segments presented in the scope
• Key Market Developments and financials of the key players
• Opportunity Analysis for the new entrants
• SWOT Analysis of the key players
• Fastest growing markets analyzed during the forecast period

Key Topics Covered

1 Market Synopsis

2 Research Outline

3 Market Dynamics

3.1 Drivers

3.2 Restraints

4 Market Environment

4.1 Bargaining power of suppliers

4.2 Bargaining power of buyers

4.3 Threat of substitutes

4.4 Threat of new entrants

4.5 Competitive rivalry

5 Global Orphan Drugs Market, By Drug Type

5.1 Introduction

5.2 Biologics

5.3 Non-Biologics

6 Global Orphan Drugs Market, By Therapy Class

6.1 Introduction

6.2 Blood

6.3 Central Nervous Systems

6.4 Endocrine

6.5 Respiratory

6.6 Dermatology

6.7 Systemic Anti-Infectives

6.8 Musculoskeletal

7 Global Orphan Drugs Market, By Drug

7.1 Introduction

7.2 Adcetris

7.3 Darzalex

7.4 Imbruvica

7.5 Jakaf

7.6 Keytruda

7.7 Opdivo

7.8 Pomalyst

7.9 Revlimid

7.10 Rituxan

7.11 Soliris

7.12 Spinraza

7.13 Copaxone

7.14 Avonex

7.15 Sensipar

7.16 Hemlibra

7.17 Venclexta

7.18 Epidiolex

8 Global Orphan Drugs Market, By Disease Type

8.1 Introduction

8.2 Cardiovascular Diseases

8.3 Hematologic and Immunologic Diseases

8.4 Infectious Diseases

8.5 Metabolic Diseases

8.6 Neurologic Diseases

8.7 Oncological Diseases

8.8 Gastrointestinal

8.9 Pulmonary

9 Global Orphan Drugs Market, By Indication

9.1 Introduction

9.2 Acute Myeloid Lukemia

9.3 Cystic Fibrosis

9.4 Duchenne Muscular Dystrophy

9.5 Glioma

9.6 Graft vs Host Disease

9.7 Multiple Myeloma

9.8 Non-Hodgkin’s Lymphoma

9.9 Ovarian Cancer

9.10 Pancreatic Cancer

9.11 Renal Cell Carcinoma

9.12 Other Indications

10 Global Orphan Drugs Market, By Phase

10.1 Introduction

10.2 Phase I

10.3 Phase II

10.4 Phase III

10.5 Phase IV

11 Global Orphan Drugs Market, By Distribution Channel

11.1 Introduction

11.2 Hospital Pharmacy

11.3 Online Sales

11.4 Retail Pharmacy

11.5 Specialty Pharmacies

11.6 Other Distribution Channels

12 Global Orphan Drugs Market, By Geography

12.1 North America

12.2 Europe

12.3 Asia Pacific

12.4 South America

12.5 Middle East & Africa

13 Strategic Benchmarking

14 Vendors Landscape

14.1 Alexion Pharmaceuticals Inc.

14.2 Amgen Inc.

14.3 AstraZeneca PLC

14.4 Bayer AG

14.5 Bristol-Myers Squibb Company

14.6 Celgene Corporation

14.7 Daiichi Sankyo Company Limited

14.8 GlaxoSmithKline PLC

14.9 Hoffmann-La Roche Ltd.

14.10 Merck & Co. Inc.

14.11 Novartis AG

14.12 Novo Nordisk A/S

14.13 Teva Pharmaceutical Industries Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/3bfbkm

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900